Table 4. Multivariate COX regression analysis of the association of Ano1 expression and clinicopathological features with RFS and OS in breast cancer patients.
| Survival | RFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total n | Events n (%) | Adjusted HR (95%CI) † | p † | Total n | Events N (%) | Adjusted HR (95%CI) † | p † | ||
| Ano1 Expression | |||||||||
| ER positive patients | |||||||||
| Low | 112 | 7 (6.3) | 1 (reference) | 112 | 16 (14.3) | 1 (reference) | |||
| High | 156 | 18 (11.5) | 1.758 (0.728–4.242) | 0.209 | 156 | 12 (7.7) | 0.497 (0.234–1.058) | 0.070 | |
| ER negative patients | |||||||||
| Low | 58 | 6 (10.3) | 1 (reference) | 58 | 10 (17.2) | 1 (reference) | |||
| High | 69 | 5 (7.2) | 0.575 (0.168–1.960) | 0.376 | 69 | 10 (14.5) | 0.869 (0.355–2.129) | 0.759 | |
| PR positive patients | |||||||||
| Low | 106 | 10 (9.4) | 1 (reference) | 106 | 16 (15.1) | 1 (reference) | |||
| High | 160 | 16 (10.0) | 0.966 (0.447–2.221) | 0.993 | 160 | 11 (6.9) | 0.411 (0.190–0.893) | 0.025 | |
| PR negative patients | |||||||||
| Low | 64 | 3 (4.7) | 1 (reference) | 64 | 10 (15.6) | 1 (reference) | |||
| High | 65 | 7 (10.8) | 1.986 (0.510–7.727) | 0.322 | 65 | 11 (16.9) | 1.018 (0.429–2.419) | 0.967 | |
| HER2 positive patients | |||||||||
| Low | 93 | 7 (7.5) | 1 (reference) | 93 | 16 (17.2) | 1 (reference) | |||
| High | 135 | 14 (10.4) | 1.292 (0.517–3.226) | 0.583 | 135 | 19 (14.1) | 0.800 (0.411–1.559) | 0.512 | |
| HER2 negative patients | |||||||||
| Low | 77 | 6 (7.8) | 1 (reference) | 77 | 10 (13.0) | 1 (reference) | |||
| High | 90 | 9 (10.0) | 1.100 (0.384–3.154) | 0.859 | 90 | 3 (3.3) | 0.250 (0.068–0.920) | 0.037 | |
| Tamoxifen treatment | |||||||||
| Low | 123 | 10 (8.1) | 1 (reference) | 123 | 18 (14.6) | 1 (reference) | |||
| High | 182 | 20 (11.0) | 1.268 (0.590–2.727) | 0.543 | 182 | 14 (7.7) | 0.491 (0.243–0.990) | 0.047 | |
| Anthracycline alone or combined with Paclitaxel | |||||||||
| Low | 149 | 12 (8.1) | 1 (reference) | 149 | 21 (14.1) | 1 (reference) | |||
| High | 199 | 19 (9.5) | 0.552 (0.137–2.227) | 0.404 | 199 | 18 (9.0) | 1.416 (0.373–5.373) | 0.610 | |
| Clininopathological features | |||||||||
| Age (years) | |||||||||
| <51 | 210 | 23 (11.0) | 1 (reference) | 210 | 21 (10.0) | 1 (reference) | |||
| ≥51 | 185 | 13 (7.0) | 0.696 (0.191–2.535) | 0.583 | 185 | 27 (14.6) | 1.113 (0.350–3.539) | 0.855 | |
| Menopausal status | |||||||||
| Premenopausal | 205 | 22 (10.7) | 1 (reference) | 205 | 20 (9.8) | 1 (reference) | |||
| Postmenopausal | 190 | 14 (7.4) | 0.913 (0.255–3.266) | 0.889 | 190 | 28 (14.7) | 1.414 (0.442–4.529) | 0.559 | |
| First-degree family history of cancer | |||||||||
| No | 332 | 27 (8.1) | 1 (reference) | 332 | 39 (11.7) | 1 (reference) | |||
| Yes | 63 | 9 (14.3) | 1.609(0.753–3.434) | 0.219 | 63 | 9 (14.3) | 1.101 (0.532–2.279) | 0.795 | |
| Tumor size (cm) | |||||||||
| ≤ 2.0 | 134 | 11 (8.2) | 1 (reference) | 134 | 6 (4.5) | 1 (reference) | |||
| >2.0 | 261 | 25 (9.6) | 1.109 (0.541–2.272) | 0.778 | 261 | 42 (16.1) | 3.798 (1.611–8.953) | 0.002 | |
| Clinical stage | |||||||||
| I or II | 281 | 21 (7.5) | 1 (reference) | 281 | 13 (4.6) | 1 (reference) | |||
| III or IV | 114 | 15 (13.2) | 1.951 (1.002–3.797) | 0.049 | 114 | 35 (30.7) | 7.961 (4.203–15.076) | <0.001 | |
| Lymph node metastasis | |||||||||
| Node-negative | 194 | 14 (7.2) | 1 (reference) | 194 | 10 (5.2) | 1 (reference) | |||
| Node-positive | 201 | 22 (10.9) | 1.712 (0.874–3.353) | 0.117 | 201 | 38 (18.9) | 4.030 (2.006–8.096) | <0.001 | |
Abbreviations: HR: Hazard Ratio; 95% CI, 95% confidence interval; RFS: Recurrence-free survival; OS: Overall survival; Ref, reference category; ER, Estrogen receptor; PR, Progesterone receptor; HER2, Human epidermal growth factor receptor.
† p values, Adjusted HR (95%CI) were assessed using multivariate Cox regression analysis adjusted for age and menopause status.